New York, New York–(Newsfile Corp. – March 16, 2022) – Plantable® Health Inc. (NEO: PLBL) (“Plantable“or the”Company“) today announces that its clinically supported restart program is now eligible for reimbursement through Health Savings Accounts (“HSA“) in the United States, offering up to 50% savings by paying with pre-tax HSA dollars. In 2020 alone, HSA asset growth increased by 25% year-over-year , to reach $82.2 billion in assets held in more than 30 million accounts, with an average HSA balance of more than $1,690 in the 45-65+ age bracket.
To view an enhanced version of this graphic, please visit:
Plantable is a customer-focused company and HSA eligibility is the first of the company’s initiatives to bring even more affordable and a proven intervention on the lifestyle of many people, tackling the burgeoning chronic disease epidemic. Academic research has directly linked diet to the most common chronic diseases, including prediabetes, type 2 diabetes, high blood pressure, high cholesterol, and even some forms of cancer, and these conditions can be reversed with sustained dietary change. Results of the Reboot program showed a reduction in blood sugar (as measured by HgbA1C – a common marker for pre- and type II diabetes), a reduction in LDL3 and a reduction in inflammation3 (as measured by hsCRP), a biomarker of possible cardiovascular disease. 93% of Reboot clients surveyed attested that the Reboot program achieved their weight and/or health goals, and 54% certified long-term sustained improvement, with 86% attributing the lasting change to their participation in the Reboot program3.
With active clinical trials underway at major US medical institutions, HSA eligibility is Plantable’s first step in its broader insurance coverage initiative. The Company anticipates that the successful conclusion of its ongoing clinical trials will lead to Phase III clinical trials and future collaboration with insurance companies. The exploding cost of chronic disease management, coupled with the payer’s desire to reimburse value-based outcomes, positions Plantable’s Reboot program well for reimbursement. The Company has begun to nurture relationships with insurance companies in the United States as consumer demand for health insurance companies to cover the costs of alternative medicine continues to increase..
CEO Dr Nadja Pinnavaia said: “Plantable’s mission is to reverse diet-related chronic diseases through sustained, long-term dietary change. We all know behavior change is hard, but Plantable’s Reboot program makes it easier. , with results to prove it.Our HSA eligibility now opens more doors, making reversing chronic conditions such as pre-diabetes and other metabolic diseases more accessible, while paving the way for future HSA coverage. insurance.”
Patients who purchase the reboot, to treat chronic conditions such as pre-diabetes, type 2 diabetes, high blood pressure, high cholesterol, and a BMI (body mass index) over 30, are considered eligible to HSA reimbursement. To learn more about HSA submission, please click here.
About Plantable® Health Inc.
Plantable is a clinically backed lifestyle intervention program that combines behavioral psychology, neuroscience, and nutritional science to transform health and wellness. Plantable leads to healthy weight loss and improved health and well-being through effective behavior change. Plantable’s effectiveness is built on the science behind plant-based nutrition, personalized coaching and lifestyle education tools to empower people to change their eating habits. To view the company’s products and become a customer, please visit plantable.com or click the link here: https://plantable.com
If you are interested in investing in the Company and would like more information, click on the link here: http://invest-plantable.com
Become a member of the Plantable Investor Community on WhatsApp by joining the link here: https://chat.whatsapp.com/CNupoG2sVitJRhzpfGJGHt
On behalf of the Board of Directors,
Dr Nadja Pinnavaia
Chief executive officer
For investor inquiries, please contact:
Corporate Communication and Investor Relations
Caution Regarding Forward-Looking Information
Certain statements contained in this press release constitute forward-looking statements within the meaning of applicable securities laws. All statements contained in this press release, other than statements of historical facts, which address events or developments expected by the management of the Company, are forward-looking statements. Specifically, references in this press release to the benefits the Company expects to derive from Health Savings Account eligibility, and expected market opportunities arising from future collaboration with insurance companies both are forward-looking statements. Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond the control of the Company, which could cause actual results and events to differ materially from those disclosed or implied by such forward-looking statements, see “Notice to Investors – Forward-Looking Information” and “Risk Factors” in the Prospectus. The Company disclaims any intention or obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable securities laws.
 The Cost of Chronic Disease, Milken Institute, August 2018
 Further information on the clinical trials and results of the Reboot program is available in the amended and updated prospectus which is available under the Company’s profile on SEDAR at sedar.com.
 Note: The Plantable Reboot program is non-refundable. It is recommended that all customers contact their HSA provider prior to program purchase to verify coverage as HSA program requirements may vary across the United States.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/116930